Heparin Plus Insulin No Better Than Insulin Alone for Pancreatitis Caused by High Triglycerides
A 533-patient Chinese RCT finds adding LMWH to insulin doesn't reduce organ failure or death in hypertriglyceridemic acute pancreatitis.
Summary
A multicenter randomized trial across 13 Chinese hospitals tested whether adding low-molecular-weight heparin (LMWH) to insulin improves outcomes in acute pancreatitis triggered by very high triglycerides. Among 533 adults, the composite of new-onset organ failure and/or 30-day mortality occurred in 25% of the LMWH-plus-insulin group versus 28.3% with insulin alone—a non-significant difference. Both groups achieved the triglyceride target below 500 mg/dL within a median of 2 days. Bleeding events, triglyceride rebound, and other adverse events were similar. The findings suggest that adding LMWH to insulin provides no meaningful clinical benefit and may be unnecessary in routine management of hypertriglyceridemic acute pancreatitis.
Detailed Summary
Hypertriglyceridemic acute pancreatitis (HTG-AP) is a serious and increasingly common condition, particularly in China where elevated triglycerides now account for more than 25% of acute pancreatitis cases. Compared with gallstone or alcohol-related pancreatitis, HTG-AP tends to produce more severe systemic inflammation, higher rates of persistent organ dysfunction, more local complications, and greater mortality. Despite the clinical urgency of rapidly lowering triglycerides, no high-quality evidence previously guided the choice among insulin, heparin, their combination, or blood purification. Both insulin and heparin activate lipoprotein lipase to accelerate triglyceride clearance, and their combination has been widely used empirically—but without rigorous trial data.
This multicenter, open-label, parallel-group, superiority randomized clinical trial enrolled 533 adults aged 18–85 years at 13 tertiary hospitals in China between September 2019 and April 2023. Eligible patients had confirmed acute pancreatitis, baseline serum triglycerides between 1000 and 3550 mg/dL, and presented within 48 hours of symptom onset. Participants were randomized to subcutaneous LMWH (4000 IU every 12 hours for 3 days) plus insulin (n=264) or insulin alone (n=269). The primary composite endpoint was new-onset organ failure and/or all-cause mortality within 30 days. The study was powered as a superiority trial.
The primary endpoint occurred in 66 patients (25.0%) in the LMWH-plus-insulin group versus 76 patients (28.3%) in the insulin-alone group (relative risk 0.89; 95% CI, 0.67–1.17; P=.40), failing to demonstrate superiority. Both groups achieved the triglyceride target of less than 500 mg/dL in a median of 2 days (P=.94), indicating equivalent lipid-lowering speed. Safety outcomes were also comparable: new-onset bleeding events (RR 0.61; 95% CI, 0.15–2.53; P=.73), triglyceride rebound (RR 0.53; 95% CI, 0.28–1.01; P=.05), and drug-related adverse events (RR 0.79; 95% CI, 0.30–2.10; P=.64) did not differ significantly between arms.
The results carry important clinical and pharmacological implications. Because insulin alone achieves equivalent triglyceride lowering as rapidly as the combination, the additional activation of lipoprotein lipase by LMWH appears clinically redundant in this setting. The lack of benefit on organ failure and mortality suggests that the speed of triglyceride reduction achieved by insulin alone is already sufficient, and that residual disease severity may be driven by mechanisms beyond circulating triglyceride levels—such as free fatty acid toxicity, inflammatory cascades, or microvascular injury—that neither drug addresses directly.
Several caveats temper these conclusions. The trial was open-label, which may introduce performance or assessment bias. The study population was predominantly younger (median age 39 years), male (76%), and Chinese, limiting generalizability to older or more ethnically diverse populations. The upper triglyceride cutoff of 3550 mg/dL excluded the most extreme cases, and the lack of a placebo-controlled insulin-alone arm means absolute effects of insulin itself on outcomes remain untested. Nonetheless, this is the largest and most rigorous RCT to date in HTG-AP, providing strong evidence against routine LMWH addition to insulin in this condition.
Key Findings
- LMWH plus insulin did not reduce new-onset organ failure or 30-day mortality vs insulin alone (25.0% vs 28.3%; P=.40).
- Both groups reached the triglyceride target (<500 mg/dL) in a median of 2 days with no significant difference.
- Bleeding events, triglyceride rebound, and drug-related adverse events were statistically similar between groups.
- Results suggest LMWH adds no meaningful clinical benefit when insulin is already given for lipid lowering in HTG-AP.
- Study is the largest RCT to date in hypertriglyceridemic acute pancreatitis, enrolling 533 patients across 13 centers.
Methodology
Multicenter, open-label, parallel-group, superiority RCT at 13 Chinese tertiary hospitals (2019–2023), enrolling 533 adults with HTG-AP (triglycerides 1000–3550 mg/dL) admitted within 48 hours of onset. Participants were randomized to subcutaneous LMWH 4000 IU every 12 hours for 3 days plus insulin versus insulin alone, with 30-day follow-up. The primary composite endpoint was new-onset organ failure and/or all-cause mortality.
Study Limitations
The open-label design introduces potential performance and assessment bias since neither patients nor clinicians were blinded. The predominantly young, male, Chinese cohort with triglycerides capped at 3550 mg/dL limits generalizability to other populations and the most extreme hypertriglyceridemia. There was no placebo arm, so the absolute benefit of insulin itself on clinical outcomes compared with no lipid-lowering therapy remains unquantified.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.